The potential of volatile organic compound analysis for pathogen detection and disease monitoring in patients with cystic fibrosis

Expert Rev Respir Med. 2022 Jul;16(7):723-735. doi: 10.1080/17476348.2022.2104249. Epub 2022 Aug 1.

Abstract

Introduction: Airway infection with pathogens and its associated pulmonary exacerbations (PEX) are the major causes of morbidity and premature death in cystic fibrosis (CF). Preventing or postponing chronic infections requires early diagnosis. However, limitations of conventional microbiology-based methods can hamper identification of exacerbations and specific pathogen detection. Analyzing volatile organic compounds (VOCs) in breath samples may be an interesting tool in this regard, as VOC-biomarkers can characterize specific airway infections in CF.

Areas covered: We address the current achievements in VOC-analysis and discuss studies assessing VOC-biomarkers and fingerprints, i.e. a combination of multiple VOCs, in breath samples aiming at pathogen and PEX detection in people with CF (pwCF). We aim to provide bases for further research in this interesting field.

Expert opinion: Overall, VOC-based analysis is a promising tool for diagnosis of infection and inflammation with potential to monitor disease progression in pwCF. Advantages over conventional diagnostic methods, including easy and non-invasive sampling procedures, may help to drive prompt, suitable therapeutic approaches in the future. Our review shall encourage further research, including validation of VOC-based methods. Specifically, longitudinal validation under standardized conditions is of interest in order to ensure repeatability and enable inclusion in CF diagnostic routine.

Keywords: Breath analysis; Pseudomonas aeruginosa; cystic fibrosis; pathogens; volatile organic compounds.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Breath Tests
  • Cystic Fibrosis*
  • Humans
  • Volatile Organic Compounds*

Substances

  • Biomarkers
  • Volatile Organic Compounds